Menu
Close
Funded Projects

Proteomic exploration of lung matrisome in pulmonary fibrosis: role of MRC2

Awarded in 2024
Collaborative Health Sciences Program
Updated Apr 24, 2025

At a Glance

Idiopathic pulmonary fibrosis (IPF) is a fatal lung condition where tissue becomes scarred and hardened, and its prevalence in the United States is increasing. Using cutting edge proteomics and bioinformatics technologies and methodologies, researchers aim to better understand how fibrosis happens in order to find ways to reverse it. The project will lay the groundwork for the development of precise therapeutics tailored to combat fibrotic lung alterations.

More Funded Projects

research icon: microscope and stethoscope
Collaborative Health Sciences Program

Synergizing OXPHOS-inhibitors and innate T cell-DC cellular immunotherapy to treat ovarian cancer

Year Awarded: 2024
This project focuses on developing and testing a new strategy to treat ovarian cancer. Ovarian cancer is a daunting diagnosis because it is a rapidly progressive and metastatic type of cancer, and most people are diagnosed at a late stage of disease. Researchers will test an approach of using dendritic cells to stimulate patient T cells and induce an anti-tumor immune response in patients with ovarian cancer. This project lays the foundation for potential future clinical trials to test this novel approach to train patients’ own immune cells to find and eradicate their ovarian cancer.
research icon: microscope and stethoscope
Collaborative Health Sciences Program

Preclinical evaluation of a novel theranostic MET-directed variable new antigen receptor (VNAR) single-domain antibody in MET-altered lung cancer

Year Awarded: 2024
This project aims to develop a novel treatment for non-small cell lung cancer, the leading cause of cancer death in the United States and Wisconsin, by using a unique shark-derived antibody. The goal is to improve treatment outcomes for patients who have an abnormal MET protein and a generally worse prognosis. Researchers will focus on creating a highly targeted therapy that combines radiation with this specialized antibody to attack cancer cells more effectively.